On 31 January 2008, orphan designation EU/3/07/525 was granted by the European Commission to Molecular Insight Limited, United Kingdom, for iodine (131I) iobenguane for the treatment of neuroblastoma.
Iodine (131I) iobenguane
Treatment of neuroblastoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Excelsior Life Sciences Ireland Limited
|March 2023||The sponsor's address was updated.|
|June 2019||The sponsorship was transferred to Excelsior Life Sciences Ireland Limited, Ireland.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: